- Treatment of HCV genotype 1, 2, 3, or 4 as a component of a combination antiviral treatment regimen
- Indicated in patients with hepatocellular carcinoma, those awaiting liver transplantation, and those with HCV/HIV-1 co-infection
- Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin
NON-FDA APPROVED USES
- In combination with an HCV active antiviral regimen, sofosbuvir’s (SOF) efficacy has been established in patients with HCV genotypes 5 and 6
There's more to see -- the rest of this topic is available only to subscribers.